canakinumab
novartis
['nsclc', 'canakinumab', 'lung', 'sclc', 'canopy-a']
the #oncoalerttoptweet #esmo22 day 3 tweet oncoalert colleague canopy-a: phase iii study of
canakinumab as adjuvant
therapy in patients with
completely resected non-small cell
lung cancer #nsclc best 
?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ??